These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Ex vivo transfer of the decorin gene into rat glomerulus via a mesangial cell vector suppressed extracellular matrix accumulation in experimental glomerulonephritis.
    Author: Huijun W, Long C, Zhigang Z, Feng J, Muyi G.
    Journal: Exp Mol Pathol; 2005 Feb; 78(1):17-24. PubMed ID: 15596056.
    Abstract:
    The activation of transforming growth factor-beta (TGF-beta) is known to be one of the major causes of glomerulosclerosis. Decorin (DCN) is a natural inhibitor of TGF. The purpose of this study was to assess the feasibility of transferring the DCN gene to antithymocyte serum (ATS) glomerulonephritis glomeruli via a mesangial cell vector to treat glomerulonephritis fibrosis. For this process, the recombinant eukaryotic expression plasmid pcDNA3.1A-DCN was constructed and transfected into mesangial cell. The DCN-positive cloned cells were transferred to rat antithymocyte serum glomeruli by a left renal artery injection. Using immunohistochemical staining, approximately 37-60% (48.6% +/- 11.34%; mean +/- SE, n = 8) of the glomeruli were BrdU-positive in the injected-side kidney. DCN proteins were observed in the cytoplast beginning 12 h after injection. TGF-beta1 expression in the injected side glomeruli decreased significantly at day 4 (P < 0.05), compared with that in the uninjected-side kidney. The expression leaves of fibronectin and collagen IV decreased significantly at days 1-2 (P < 0.01) and day 4 (fibronectin, P < 0.01; collagen IV, P < 0.05). These results suggest that the use of DCN can decrease antithymocyte serum glomerulonephritis extracellular matrix (ECM) ingredients and that such use offers a favorable experimental basis for gene therapy for kidney disease.
    [Abstract] [Full Text] [Related] [New Search]